Myfembree

Active Ingredient(s): Estradiol + Norethindrone Acetate + Relugolix
FDA Approved: * May 26, 2021
Pharm Company: * MYOVANT SCIENCES
Category: Women's Health / Fertility

Relugolix/estradiol/norethisterone acetate (RGX/E2/NETA), sold under the brand name Myfembree, is a fixed-dose combination hormonal medication which is used for the treatment of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.[1][2] It contains relugolix, an orally active gonadotropin-releasing hormone antagonist (GnRH antagonist), estradiol (E2), an estrogen, and norethisterone acetate (NETA), a progestin.[... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Myfembree Oral Tablet, Film Coated
NDC: 72974-415
Labeler:
Myovant Sciences, Inc.